Tocilizumab — CPB 0799 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0799 governing tocilizumab coverage, effective February 25, 2026. Here's what billing teams need to know before submitting claims for J3262, Q5133, Q5135, or Q5156.

Aetna's tocilizumab coverage policy under CPB 0799 Aetna system now covers four products: the reference biologic Actemra (J3262) and three biosimilars—Tofidence (Q5133), Tyenne (Q5135), and Avtozma (Q5156). The policy spans a wide range of indications, from rheumatoid arthritis and juvenile idiopathic arthritis to cytokine release syndrome, Castleman disease, and immune checkpoint inhibitor toxicity. If your practice bills tocilizumab infusions or injections under any of these codes, this update changes how you document medical necessity and which prescriber specialties can authorize treatment.

Quick-Reference Table

Aetna Tocilizumab Coverage Criteria and Medical Necessity Requirements 2026

Aetna's CPB 0799 coverage policy requires prior authorization for every tocilizumab product across all applicable commercial plan designs. No exceptions. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. You can also access Statement of Medical Necessity forms through Aetna's Specialty Pharmacy Precertification portal.

The first gate is prescriber specialty. Aetna won't approve tocilizumab billing unless the ordering provider meets specific specialty requirements tied to the indication:

If your claim shows a primary care physician or hospitalist as the prescriber, expect a claim denial unless a qualifying specialist was involved in the treatment decision.

Medical Necessity: Rheumatoid Arthritis

For adult RA patients, Aetna considers tocilizumab medically necessary in two paths. First, the member previously received a biologic or targeted synthetic drug—such as Rinvoq (upadacitinib) or Xeljanz (tofacitinib)—indicated for moderately to severely active RA. That prior treatment history alone satisfies the requirement.

Second, if the member has no prior biologic history, Aetna requires documented biomarker testing. Either rheumatoid factor (RF, CPT 86430 or 86431) or anti-CCP antibodies (CPT 86200) must be positive. Alternatively, the member must have been tested for all three: RF, anti-CCP, and CRP (CPT 86140 or 86141) and/or ESR (CPT 85651 or 85652). That last path—testing all markers regardless of result—gives providers a route to approval even when individual markers are negative. Document every test result in the chart before submitting.

Medical Necessity: Juvenile Idiopathic Arthritis

For articular JIA, the member must be at least two years old. Like RA, there are two paths. Prior biologic or targeted synthetic drug use satisfies the requirement directly. If no prior biologic history exists, the member needs documented inadequate response to methotrexate or another conventional synthetic DMARD (leflunomide, sulfasalazine, hydroxychloroquine). Alternatively, the member must have had inadequate response to scheduled NSAIDs and/or intra-articular glucocorticoids (triamcinolone hexacetonide, J3303) plus at least one risk factor for poor outcome—joint involvement at the ankle, wrist, hip, sacroiliac joint, or TMJ; erosive disease; or enthesitis.

Site of Care Requirements

For intravenous tocilizumab, Aetna's Site of Care Utilization Management Policy applies to commercial plans. This is separate from CPB 0799 but directly affects reimbursement for infusion services billed under CPT 96365–96368. If your practice is an independent infusion center or physician office, verify site-of-care approval before scheduling IV administration. Aetna may redirect patients to lower-cost settings. Subcutaneous tocilizumab (J3262 and Q5135) is not subject to the same site-of-care restrictions.

Aetna Tocilizumab Exclusions and Non-Covered Indications

The policy restricts subcutaneous formulations specifically. For systemic sclerosis-associated ILD, only the subcutaneous formulation is allowed—the HCPCS descriptions for J3262 and Q5135 explicitly note this restriction. Tofidence (Q5133) is listed as intravenous use only.

For Medicare-covered members, this policy does not apply. Aetna directs Medicare billing to its separate Medicare Part B criteria. Don't apply CPB 0799 criteria to Medicare Advantage claims unless you've confirmed the plan uses commercial CPB 0799 standards—some MA plans do, some don't. If you're unsure how a specific plan design maps, call Aetna provider services before submitting.

COVID-19 indications are addressed through separate HCPCS codes (M0237, M0238, M0249, M0250, Q0237, Q0249) and are not part of the core CPB 0799 medical necessity pathway for commercial plans.

Coverage Indications at a Glance

Aetna Tocilizumab Billing Guidelines and Action Items 2026

The effective date of February 25, 2026 means these criteria are active now. If your team hasn't already audited claims submitted after that date, do it this week.

If your tocilizumab billing volume is significant and you have patients spanning multiple indications, talk to your compliance officer about whether your current documentation templates capture all the required elements under this updated policy. The prescriber specialty and biomarker documentation requirements are the two areas most likely to generate denials if your intake process hasn't been updated.

CPT, HCPCS, and ICD-10 Codes for Tocilizumab Under CPB 0799

HCPCS Codes Covered When Selection Criteria Are Met